Celgene's β-thalassemia blockbuster luspatercept nears finish line

Celgene's luspatercept is on track for a dual approval after FDA on Tuesday accepted a BLA for the therapy to treat β-thalassemia and

Read the full 237 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE